These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12846176)

  • 21. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
    Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R;
    AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Ramírez-Hernández M; Sánchez-Sierra B; Martínez-Escribano JA
    Acta Derm Venereol; 2007; 87(5):442-3. PubMed ID: 17721659
    [No Abstract]   [Full Text] [Related]  

  • 23. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 24. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ester derivatives of nucleoside inhibitors of reverse transcriptase: II. Molecular systems for combined therapy with 3'-azido-3'-deoxythymidine and 2',3'-didehydro-3'-deoxythymidine].
    Berezovskaia IuV; Chudinov MV
    Bioorg Khim; 2005; 31(5):451-65. PubMed ID: 16245688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which ART regimen is best after receipt of single-dose nevirapine?
    Ryan CT
    AIDS Clin Care; 2009 Jan; 21(1):6. PubMed ID: 19230057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
    Estrada V; de Villar N; Serrano-Ríos M
    Med Clin (Barc); 2001 Mar; 116(12):479. PubMed ID: 11333714
    [No Abstract]   [Full Text] [Related]  

  • 30. Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence.
    Steele RH; Keogh GL; Quin J; Fernando SL; Stojkova V
    Int J STD AIDS; 2002 Nov; 13(11):748-54. PubMed ID: 12437894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N; Pathipvanich P; Yasuda T; Mukoyama Y; Rojanawiwat A; Matsubayashi T; Saeng-aroon S; Auwanit W; Matsuyama A; Sawanpanyalert P; Ariyoshi K
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
    Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA advisory on nevirapine.
    AIDS Treat News; 2005 Jan; (409):7. PubMed ID: 15791716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
    Raffi F; Lewden C; Chêne G
    AIDS; 2008 Jan; 22(3):435-6. PubMed ID: 18195573
    [No Abstract]   [Full Text] [Related]  

  • 35. Thailand markets low-cost, 3-in-1 antiretroviral medication.
    AIDS Policy Law; 2002 Apr; 17(8):8. PubMed ID: 12004875
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
    J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
    Charpentier C; Laureillard D; Sodqi M; Si-Mohamed A; Karmochkine M; Bélec L; Weiss L; Piketty C
    J Clin Virol; 2008 Oct; 43(2):212-5. PubMed ID: 18760662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C; Kouanfack C; Koulla-Shiro S; Njoume M; Nkene YM; Ciaffi L; Brulet C; Peytavin G; Vergne L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    AIDS; 2007 Mar; 21(6):768-71. PubMed ID: 17413701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA notifications. FDA gives tentative approval for stavudine, lamivudine & nevirapine tablet.
    AIDS Alert; 2009 Sep; 24(9):105-6. PubMed ID: 19938312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.